Mergers and Acquisitions

Lilly to Acquire Non-Opioid Pain Asset from Centrexion

May 28, 2019

Eli Lilly is set to acquire exclusive worldwide rights for potential non-opioid treatment CNTX-0290 from Centrexion Therapeutics in a deal potentially worth $997.5 million.

Thermo Fisher to Acquire Manufacturing Site from GSK

May 16, 2019

The acquisition of GlaxoSmithKline’s manufacturing site in Cork, Ireland, will expand Thermo Fisher Scientific’s global footprint for complex API manufacturing.

Lundbeck to Acquire Abide Therapeutics

May 15, 2019

The acquisition provides Valby, Denmark-based Lundbeck with a discovery platform and a US-based research hub.

Pfizer to Acquire Biotech Firm Therachon in Deal Worth $810 Million

May 13, 2019

The acquisition will expand Pfizer’s rare disease portfolio with an early pipeline candidate for treating dwarfism.

Newly Combined CRO to Launch at DIA 2019

May 10, 2019

Research Point Global and WuXi Clinical Development Services have revealed that they are to combine and rebrand as a new CRO, WuXi Clinical.

Novartis to Acquire Takeda Eye-Care Drug in Deal Worth Up to $5.3 Billion

May 10, 2019

Novartis will acquire assets associated with Takeda Pharmaceuticals’ Xiidra (lifitegrast ophthalmic solution) 5%, an eye-care drug.

SGS Acquires Chemical Solutions

May 07, 2019

The acquisition is expected to strengthen SGS’s agriculture, food, and life business in the United States.

Lilly Sells Legacy Antibiotics Brands and Manufacturing Facility in China

April 24, 2019

Eli Lilly sold rights to two of its legacy antibiotics as well as its Suzhou, China, manufacturing facility, to China-based specialty pharmaceutical company Eddingpharm in a deal worth $375 million.

Protagen Protein Services, BioAnalytix Merge into CRO

April 16, 2019

Pharmaceutical Technology's In the Lab eNewsletter

The companies will merge to offer a broader range of analytical data packages and regulatory support for biopharmaceuticals.

Bristol-Myers Squibb Shareholders Approve Celgene Acquisition

April 12, 2019

Shareholders have approved the issuance of Bristol-Myers Squibb common stock for the pending $74-billion merger with Celgene.